Single-Cell eQTL Market to Hit $4.51 Billion by 2030

The global market for single-cell expression quantitative trait locus (eQTL) clinical workflows is on a trajectory of significant growth, driven by increased investments in genomic analysis by healthcare and life sciences sectors. According to a report by ResearchAndMarkets.com, the market expanded from $1.82 billion in 2025 to $2.18 billion in 2026, marking a compound annual growth rate (CAGR) of 19.6%1. This upward trend is expected to continue, with projections indicating the market will reach $4.51 billion by 2030, growing at a CAGR of 19.9%2.

Several factors are fueling this growth, including the adoption of advanced single-cell sequencing technologies, the integration of artificial intelligence in genomic data analysis, and the expansion of personalized medicine programs. The market is also benefiting from the integration of cloud-based platforms and automation in sample and library preparation processes. Key trends in the market include high-resolution gene expression mapping, automated workflow pipelines, and predictive biomarker discovery.

The demand for single-cell eQTL clinical workflows is largely driven by the increasing adoption of precision medicine. As complex and chronic diseases become more prevalent, there is a growing need for treatment strategies that are tailored to individual genetic and cellular characteristics. Single-cell eQTL workflows enable researchers and clinicians to analyze gene expression variations at the cellular level, identify patient-specific therapeutic targets, and translate genomic data into actionable clinical insights. These capabilities support more targeted treatment selection, enhance biomarker development, and improve clinical decision-making.

The market’s potential is further underscored by the rise in personalized treatments. The Personalized Medicine Coalition reports that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from six in 20223. This increase highlights the expanding role of genomic technologies in therapeutic development and underscores the demand for scalable single-cell analysis workflows.

Innovation in the field is focused on integrating whole-genome sequencing data with single-cell RNA sequencing and computational analysis. For instance, in January 2023, Singleron Biotechnologies introduced a single-cell eQTL analysis workflow within its sequencing services. This bioinformatics pipeline employs single-cell RNA sequencing and whole-genome sequencing data to predict cell-type-specific eQTLs, supporting population studies that require coordinated laboratory and computational capabilities.

Strategic acquisitions are also shaping the competitive landscape. In November 2025, QIAGEN N.V. acquired Parse Biosciences Inc. for approximately $225 million. This acquisition expands QIAGEN’s sample technologies portfolio into scalable, instrument-free single-cell sequencing, bolstering its position in AI-enabled biological research and drug discovery4. Parse Biosciences offers single-cell RNA sequencing solutions that generate high-resolution expression data for cell-type-specific eQTL analysis in clinical research.

Regionally, North America was the largest market for single-cell eQTL clinical workflows in 2025, supported by advanced genomics infrastructure and strong biotechnology investments. The Asia-Pacific region is expected to be the fastest-growing market during the forecast period, driven by increasing sequencing capacity, biomedical research, and healthcare investments. The market analysis encompasses regions such as Asia-Pacific, Southeast Asia, Western and Eastern Europe, North America, South America, the Middle East, and Africa, including countries like Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Russia, South Korea, Spain, Taiwan, the United Kingdom, and the United States.

The market is segmented by workflow type, technology, application, and end-user. Workflow types include sample preparation, library preparation, sequencing, and data analysis. Technologies covered are RNA sequencing, microarray, and PCR-based methods. Applications span disease research, drug discovery, and personalized medicine, with end-users ranging from hospitals and clinics to research institutes and pharmaceutical companies. Each of these segments plays a crucial role in the overall functionality and efficiency of single-cell eQTL workflows, contributing to the market’s robust growth.

Footnotes:

  • The market grew from $1.82 billion in 2025 to $2.18 billion in 2026. Source.
  • The market is projected to reach $4.51 billion by 2030. Source.
  • The FDA approved 16 new personalized treatments in 2023. Source.
  • QIAGEN acquired Parse Biosciences for approximately $225 million. Source.

Source

Featured Image: Megapixl @ Noipornpan

Disclaimer